CN112972410B - 一种西那卡塞药物组合物片剂及其医药用途 - Google Patents
一种西那卡塞药物组合物片剂及其医药用途 Download PDFInfo
- Publication number
- CN112972410B CN112972410B CN201911312187.8A CN201911312187A CN112972410B CN 112972410 B CN112972410 B CN 112972410B CN 201911312187 A CN201911312187 A CN 201911312187A CN 112972410 B CN112972410 B CN 112972410B
- Authority
- CN
- China
- Prior art keywords
- cinacalcet
- sieving
- pharmaceutical composition
- solution
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003315 cinacalcet Drugs 0.000 title claims abstract description 42
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000007787 solid Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 27
- 238000007873 sieving Methods 0.000 claims description 27
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 24
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 claims description 24
- 229960000478 cinacalcet hydrochloride Drugs 0.000 claims description 24
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
- 229960000987 paricalcitol Drugs 0.000 claims description 20
- 229920000881 Modified starch Polymers 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 18
- 229960002535 alfacalcidol Drugs 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 18
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 18
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 18
- 239000008107 starch Substances 0.000 claims description 18
- 235000019698 starch Nutrition 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 17
- 229910052708 sodium Inorganic materials 0.000 claims description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 16
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 16
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 12
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229920003081 Povidone K 30 Polymers 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 229960001375 lactose Drugs 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 239000007888 film coating Substances 0.000 claims description 8
- 238000009501 film coating Methods 0.000 claims description 8
- 229960003563 calcium carbonate Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 241001077909 Sigesbeckia Species 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 abstract description 15
- 229940046008 vitamin d Drugs 0.000 abstract description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 14
- 229930003316 Vitamin D Natural products 0.000 abstract description 13
- 235000019166 vitamin D Nutrition 0.000 abstract description 13
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 13
- 230000007774 longterm Effects 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 8
- 239000000314 lubricant Substances 0.000 abstract description 6
- 150000003839 salts Chemical class 0.000 abstract description 6
- 230000001133 acceleration Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000000945 filler Substances 0.000 abstract description 4
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 17
- 229940032147 starch Drugs 0.000 description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 102000003982 Parathyroid hormone Human genes 0.000 description 7
- 108090000445 Parathyroid hormone Proteins 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000000199 parathyroid hormone Substances 0.000 description 7
- 229960001319 parathyroid hormone Drugs 0.000 description 7
- 238000013112 stability test Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 201000002980 Hyperparathyroidism Diseases 0.000 description 5
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 240000003801 Sigesbeckia orientalis Species 0.000 description 3
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- -1 idecalcitol Chemical compound 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 208000025061 parathyroid hyperplasia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
Abstract
本发明属于一种西那卡塞药物组合物固体制剂及其医药用途。该西那卡塞药物组合物固体制剂包含所述西那卡塞或其可用药用盐:8.00%‑14%,维生素D类似物:0.00003%‑0.005%,黏合剂:9.50%‑25.60%,填充剂:45.50%‑75.80%;崩解剂:3.10%‑8.50%,润滑剂:0.50%‑4.60%。本发明所述西那卡塞药物组合物固体制剂,极大地改善了西那卡塞或其可药用盐和维生素D类似物组合的稳定性问题,在加速、长期试验中,均能保持稳定。此外,还可进行联合用药,起到协同作用,使得疗效得到显著提高。
Description
技术领域
本发明属于医药技术领域,具体涉及一种西那卡塞药物组合物片剂及其制备方法。
背景技术
继发性甲状旁腺功能亢进症(SHPT)是慢性肾功能衰竭患者常见的并发症,也是慢性肾衰竭终末期血液透析时最主要、最严重的并发症之一。其主要表现为甲状旁腺激素(PTH)水平升高和甲状旁腺增生,可导致严重的骨骼损害、难治皮肤瘙痒、贫血、神经系统损害及心血管疾病等。
研究显示,PTH的长期高水平状态可增加慢性肾病需要长期透析患者的死亡风险。盐酸西那卡塞是一种钙离子受体异构激动剂,作用于G-蛋白共轭型受体的钙受体,与钙离子受体结合后通过别构效应增强细胞外钙离子的作用,抑制PTH的分泌及甲状旁腺细胞的增殖。口服给药后可使血清PTH浓度降低,达到控制继发性甲状旁腺功能亢进症患者PTH水平的作用,而且本品具有在iPTH下降的同时不升高血钙的特点。
目前在我国批准用于治疗慢性肾脏病(CKD)维持透析患者的继发性甲状旁腺亢进症,用法为口服。该产品在欧美和日本,以及国内展开了多项临床药理和临床研究,结果表明其与少剂量活性维生素D联合使用治疗SHPT,可以调节血钙、血磷、钙磷乘积和矿物质以及骨质代谢,同时降低PTH水平,抑制甲状旁腺组织的增生,且不良反应发生率较单用盐酸西那卡塞低。(临床肾脏病杂志,2018,18:564-567;Nephrol Dial Transplant,2013,28:1241–1254)但目前尚无二者联合的上市产品。
将西那卡塞或其可药用盐和维生素D类似物组合后,有更好的疗效和更低的不良反应发生率,但是其稳定性受到了挑战,在稳定性考察试验中,性状颜色发生变化,含量下降,有关物质上升。因此,还需在西那卡塞或其可药用盐和维生素D类似物的药物组合物的稳定性方面继续研究,本发明采用若干种辅料制备颗粒形成片剂,大大改善了其稳定性问题,并在试验过程中发现,解决其稳定性问题,需采用几种非常规辅料,采用湿法制粒工艺,制备的干颗粒需尽快压制成片,颗粒剂或颗粒灌装胶囊,其稳定性依然存在问题。
发明内容
本发明的目的是提供一种西那卡塞药物组合物固体制剂。
本发明中采用如下技术方案:
本发明所述的一种西那卡塞药物组合物固体制剂,所述西那卡塞或其可用药用盐:8.00%-14.00%,维生素D类似物:0.00003%-0.005%,黏合剂:2.50%-15.60%,填充剂:45.50%-75.80%;崩解剂:0.50%-5.50%,润滑剂:0.50%-2.60%。
本发明所述的一种西那卡塞药物组合物固体制剂,所述黏合剂为羟丙基纤维素、甘露醇、羟丙基甲基纤维素、羧甲基纤维素、PVP/VA、聚维酮、淀粉(部分或完全预胶凝化淀粉)及甲基纤维素中的一种或几种,优选聚维酮、羟丙基纤维素。
本发明所述的一种西那卡塞药物组合物固体制剂,所述填充剂为乳糖、甘露醇、微晶纤维素、预胶化淀粉、碳酸钙等辅料中的一种或几种;优选预胶化淀粉、乳糖、碳酸钙。
本发明所述的一种西那卡塞药物组合物固体制剂,所述崩解剂为微晶纤维素、交联羧甲基纤维素钠、羟基乙酸淀粉钠、超级羧甲淀粉钠中的一种或几种;优选超级羧甲淀粉钠、交联羧甲基纤维素钠,最优选超级羧甲淀粉钠。
本发明所述的一种西那卡塞药物组合物固体制剂,所述润滑剂为豨莶脂A,且需要过40目筛。
本发明所述的一种西那卡塞药物组合物固体制剂,所述维生素D类似物包含选自帕立骨化醇、艾地骨化醇、阿法骨化醇、胆骨化醇、骨化兰醇、度骨化醇,优选帕立骨化醇、阿法骨化醇,最优选帕立骨化醇。
本发明所述的一种西那卡塞药物组合物固体制剂,所述维生素D类似物的质量为0.1ug/片-10ug/片。
本发明所述的一种西那卡塞药物组合物固体制剂,所述维生素D类似物与西那卡塞的比例为5000:1-300000:1,优选8000:1-120000:1。
本发明所述的一种西那卡塞药物组合物固体制剂,其颗粒含水量LOD%范围为1-3%。
本发明所述西那卡塞药物组合物固体制剂的制备方法,所述制备方法特征在于包含:
将西那卡塞或其可用药用盐、维生素D类似物与填充剂、黏合剂、崩解剂混合均匀,采用流化床造粒或高剪切造粒手段进行造粒,形成西那卡塞组合物湿颗粒;将湿颗粒采用高于50℃进行干燥,再将该西那卡塞组合物颗粒加入润滑剂形成片剂。其形成的片剂还进一步包括进行薄膜包衣,所述包衣材料为胃溶型薄膜包衣预混剂,包衣增重1%~5%。
本发明所述西那卡塞药物组合物片剂,极大地改善了西那卡塞或其可药用盐和维生素D类似物组合的稳定性问题,且在多种实验条件下发现仅采用本发明控制的方法制备的西那卡塞药物组合物片剂才能在加速、长期试验中,均能保持稳定。此外,还可进行联合用药,起到协同作用,使得疗效得到显著提高。
本发明还进一步包括以上所述的药物组合物固体制剂在治疗疾病的药物中的用途,所述疾病选自甲状旁腺功能亢进(HPT)、高磷血症、高钙血症与钙磷乘积提高,其中甲状旁腺功能亢进可以是继发性HPT,也可以是原发性HPT。
具体实施方式
以下将通过具体实施例进一步阐述本发明,应当理解,本发明的实施例仅用于理解本发明,而非对本发明的限制。未特别说明,本发明的术语具有本邻域的常规含义,所有试剂均为市售购得后直接使用。实施例1盐酸西那卡塞-帕立骨化醇组合物片剂
处方
名称 | 用量(mg) | 占比(%) |
盐酸西那卡塞 | 25 | 13.89 |
帕立骨化醇 | 0.0004 | 0.0002 |
微晶纤维素 | 54 | 30.00 |
乳糖 | 63 | 35.00 |
预胶化淀粉 | 27 | 15.00 |
豨莶脂A | 2 | 1.11 |
PVP-K30 | 5 | 2.78 |
超级羧甲淀粉钠 | 4 | 2.22 |
胃溶型薄膜包衣预混剂 | 5 | 2.78 |
制备工艺
①称取处方量的PVP-K30,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、帕立骨化醇、微晶纤维素、乳糖、预胶化淀粉、超级羧甲淀粉钠于湿法制粒机中混合15min。加入事先配置的PVP-K30溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③加入处方量的豨莶脂A过40目筛整粒后混合均匀。
④压片。
⑤包衣,包衣增重2%左右。
实施例2盐酸西那卡塞-阿法骨化醇组合物片剂
处方
制备工艺
①称取处方量的羟丙基纤维素,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、阿法骨化醇、微晶纤维素、碳酸钙、预胶化淀粉、超级羧甲淀粉钠于流化床中混合15min。加入事先配置的羟丙基纤维素溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③将加入处方量的豨莶脂A过40目筛整粒后混合均匀。
④压片。
⑤包衣,包衣增重2%左右。
效果实施例
为进一步理解本发明控制方法对盐酸西那卡塞-维生素D类似物组合物稳定性的改善,使用以下几个具体实施例(非本发明控制方法,实施例3-7)与上述采用本发明控制方法的具体实施例(实施例1-2)进行对比。
对比例1盐酸西那卡塞-帕立骨化醇组合物片剂
处方
名称 | 用量(mg) | 占比(%) |
盐酸西那卡塞 | 25 | 13.89 |
帕立骨化醇 | 0.0007 | 0.00038 |
微晶纤维素 | 61 | 33.89 |
碳酸钙 | 50 | 27.78 |
预胶化淀粉 | 27 | 15.00 |
微粉硅胶 | 2 | 1.11 |
羟丙基纤维素 | 8 | 4.44 |
超级羧甲淀粉钠 | 2 | 1.11 |
胃溶型薄膜包衣预混剂 | 5 | 2.78 |
制备工艺
①称取处方量的羟丙基纤维素,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、阿法骨化醇、微晶纤维素、碳酸钙、预胶化淀粉、超级羧甲淀粉钠于流化床中混合15min。加入事先配置的羟丙基纤维素溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③将加入处方量的滑石粉过40目筛整粒后混合均匀。
④压片。
⑤包衣,包衣增重2%左右。
对比例2盐酸西那卡塞-帕立骨化醇组合物片剂
处方
名称 | 用量(mg) | 占比(%) |
盐酸西那卡塞 | 25 | 13.89 |
帕立骨化醇 | 0.0007 | 0.00038 |
微晶纤维素 | 61 | 33.89 |
碳酸钙 | 45 | 25.00 |
预胶化淀粉 | 32 | 17.78 |
硬脂酸镁 | 2 | 1.11 |
羟丙基纤维素 | 8 | 4.44 |
超级羧甲淀粉钠 | 2 | 1.11 |
胃溶型薄膜包衣预混剂 | 5 | 2.78 |
制备工艺
①称取处方量的羟丙基纤维素,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、阿法骨化醇、微晶纤维素、碳酸钙、预胶化淀粉、超级羧甲淀粉钠于流化床中混合15min。加入事先配置的羟丙基纤维素溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③将加入处方量的滑石粉过40目筛整粒后混合均匀。
④压片。
⑤包衣,包衣增重2%左右。
对比例3盐酸西那卡塞-阿法骨化醇组合物片剂
处方
制备工艺
①称取处方量的羟丙基纤维素,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、阿法骨化醇、微晶纤维素、碳酸钙、预胶化淀粉、超级羧甲淀粉钠于流化床中混合15min。加入事先配置的羟丙基纤维素溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③将加入处方量的滑石粉过40目筛整粒后混合均匀。
④压片。
⑤包衣,包衣增重2%左右。
对比例4盐酸西那卡塞-帕立骨化醇组合物胶囊剂
处方
名称 | 用量(mg) | 占比(%) |
盐酸西那卡塞 | 25 | 13.89 |
帕立骨化醇 | 0.0004 | 0.0002 |
微晶纤维素 | 65 | 36.11 |
乳糖 | 42 | 23.33 |
预胶化淀粉 | 38 | 21.11 |
豨莶脂A | 2 | 1.11 |
PVP-K30 | 5 | 2.78 |
交联羧甲基纤维素钠 | 3 | 1.67 |
制备工艺
①称取处方量的PVP-K30,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、帕立骨化醇、微晶纤维素、乳糖、预胶化淀粉、交联羧甲基纤维素钠于湿法制粒机中混合15min。加入事先配置的PVP-K30溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③加入处方量的豨莶脂A过40目筛整粒后混合均匀。
④灌装胶囊。
对比例5盐酸西那卡塞-阿法骨化醇组合物片剂
处方
名称 | 用量(mg) | 占比(%) |
盐酸西那卡塞 | 25 | 13.89 |
阿法骨化醇 | 0.0004 | 0.00022 |
微晶纤维素 | 61 | 33.89 |
碳酸钙 | 50 | 27.78 |
预胶化淀粉 | 27 | 15.00 |
滑石粉 | 2 | 1.11 |
羟丙基纤维素 | 8 | 4.44 |
超级羧甲淀粉钠 | 2 | 1.11 |
胃溶型薄膜包衣预混剂 | 5 | 2.78 |
制备工艺
①称取处方量的羟丙基纤维素,纯化水配置成溶液后过200目筛备用。
②称取处方量的盐酸西那卡塞、阿法骨化醇、微晶纤维素、碳酸钙、预胶化淀粉、超级羧甲淀粉钠于流化床中混合15min。加入事先配置的羟丙基纤维素溶液进行制粒,过筛后,置于流化床中50℃沸腾干燥。
③将加入处方量的滑石粉过40目筛整粒后混合均匀。
④压片。
⑤包衣,包衣增重2%左右。
一、加速稳定性试验
依照《中国药典》2015年版四部9001原料药物与制剂稳定性试验指导原则,制剂项下规定的条件和方法,在温度为40±2℃、相对湿度75±5%的条件下考察盐酸西那卡塞-帕立骨化醇组合物片剂(批号170801-170803为实施例1、批号170701,170704,170707分别为对比例1、2、3),盐酸西那卡塞-帕立骨化醇组合物胶囊剂(批号170807-170809为对比例4)和盐酸西那卡塞-阿法骨化醇组合物片剂(170804-170806为实施例2,批号170710-170712为对比例5)的稳定性,试验结果分别见表1,2所示。
表1加速稳定性试验结果
表2加速稳定性试验结果
结果表明,盐酸西那卡塞和维生素D类似物(如:帕立骨化醇和阿法骨化醇)混合物在加速试验2月时就已发生变化,含量也发生明显下降,杂质升高,加速6月时总杂高达3.14%。采用本发明的控制方法所生产的盐酸西那卡塞-维生素D类似物(如:帕立骨化醇和阿法骨化醇)片剂(批号:170801-170803为实施例1、170804-170806为实例2)即使在苛刻的条件下仍能保持颜色的稳定,且所测定的盐酸西那卡塞和维生素D类似物(帕立骨化醇和阿法骨化醇)的含量基本不变,总杂含量控制在范围内。而没有采用本发明控制方法(如:润滑剂:豨莶脂A)制备的片剂(批号170701,170704,170707分别为对比例1、2、3,批号170710-170712为对比例5)均发生不稳定问题,含量下降,杂质升高;正如前述,采用本发明的控制方法制备的颗粒需尽快压制成片,没有采用本发明的控制方法制备片剂,直接灌装胶囊(批号:170807-170809;按照对比例4)也无法解决稳定性问题。
二、长期稳定性试验
在温度为25℃±2℃、相对湿度60%±10%的条件下对盐酸西那卡塞-帕立骨化醇组合物片剂(批号170801-170803为实施例1、批号170701,170704,170707分别为对比例1、2、3),盐酸西那卡塞-帕立骨化醇组合物胶囊剂(批号170807-170809为对比例4)和盐酸西那卡塞-阿法骨化醇组合物片剂(170804-170806为实例2,批号170710-170712为对比例5)的稳定性进行考察,分别于1个月、3个月、6个月、9个月、12个月、18个月、24个月的月末取样,并对其性状和盐酸西那卡塞和帕立骨化醇的含量进行测定,测定结果如表3,4。
表3长期稳定性试验
/>
/>
表4长期稳定性试验
/>
/>
由表3,4可知,盐酸西那卡塞和维生素D类似物(如:帕立骨化醇或阿法骨化醇)混合物在18月颜色就发生变化,且含量下降明显,杂质升高快速,长期试验24月,总杂为2.61%;而采用本发明的控制方法所生产的盐酸西那卡塞-帕立骨化醇组合物、盐酸西那卡塞-阿法骨化醇组合物片剂(批号170801-170803为实施例1、170804-170806为实施例2),在经过连续24个月的考察后,其性状和盐酸西那卡塞、帕立骨化醇、阿法骨化醇的含量均非常稳定,总杂含量也控制在范围内。而没有采用本发明控制方法(如:润滑剂:豨莶脂A)制备的片剂(批号170701,170704,170707分别为对比例1、2、3,批号170710-170712为对比例5)均发生不稳定问题,含量下降,杂质升高;以本发明处方颗粒灌装胶囊(批号:170807-170809;按照对比例4)在加速、长期过程中均不能保持稳定性。
Claims (2)
1.一种西那卡塞药物组合物固体制剂,其特征在于,处方为:
盐酸西那卡塞 25mg,
帕立骨化醇 0.0004mg,
微晶纤维素 54mg,
乳糖 63mg,
预胶化淀粉 27mg,
豨莶脂A 2mg,
PVP-K30 5mg,
超级羧甲淀粉钠 4mg,
胃溶型薄膜包衣预混剂 5mg,
所述的西那卡塞药物组合物固体制剂通过以下方法制备得到:①称取处方量的PVP-K30,纯化水配置成溶液后过200目筛备用;②称取处方量的盐酸西那卡塞、帕立骨化醇、微晶纤维素、乳糖、预胶化淀粉、超级羧甲淀粉钠于湿法制粒机中混合15min,加入事先配置的PVP-K30溶液进行制粒,过筛后,置于流化床中50 oC沸腾干燥;③加入处方量的豨莶脂A过40目筛整粒后混合均匀;④压片,⑤包衣,包衣增重2%。
2.一种西那卡塞药物组合物固体制剂,其特征在于,处方为:
盐酸西那卡塞 25mg,
阿法骨化醇 0.0007mg,
微晶纤维素 61mg,
碳酸钙 50mg,
预胶化淀粉 27mg,
豨莶脂A 2mg,
羟丙基纤维素 8mg,
超级羧甲淀粉钠 2mg,
胃溶型薄膜包衣预混剂 5mg,
所述的西那卡塞药物组合物固体制剂通过以下方法制备得到:①称取处方量的羟丙基纤维素,纯化水配置成溶液后过200目筛备用;②称取处方量的盐酸西那卡塞、阿法骨化醇、微晶纤维素、碳酸钙、预胶化淀粉、超级羧甲淀粉钠于流化床中混合15min,加入事先配置的羟丙基纤维素溶液进行制粒,过筛后,置于流化床中50 oC沸腾干燥;③将加入处方量的豨莶脂A过40目筛整粒后混合均匀;④压片;⑤包衣,包衣增重2%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911312187.8A CN112972410B (zh) | 2019-12-18 | 2019-12-18 | 一种西那卡塞药物组合物片剂及其医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911312187.8A CN112972410B (zh) | 2019-12-18 | 2019-12-18 | 一种西那卡塞药物组合物片剂及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112972410A CN112972410A (zh) | 2021-06-18 |
CN112972410B true CN112972410B (zh) | 2024-02-23 |
Family
ID=76344077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911312187.8A Active CN112972410B (zh) | 2019-12-18 | 2019-12-18 | 一种西那卡塞药物组合物片剂及其医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112972410B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114129529A (zh) * | 2021-12-27 | 2022-03-04 | 卓和药业集团股份有限公司 | 一种西那卡塞度骨化醇片及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106214651A (zh) * | 2016-08-31 | 2016-12-14 | 辰欣药业股份有限公司 | 一种枸橼酸铁片及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130085121A1 (en) * | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
-
2019
- 2019-12-18 CN CN201911312187.8A patent/CN112972410B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106214651A (zh) * | 2016-08-31 | 2016-12-14 | 辰欣药业股份有限公司 | 一种枸橼酸铁片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112972410A (zh) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130085121A1 (en) | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d | |
KR100463496B1 (ko) | 고가용성 약물용 서방성 메트리스 시스템 | |
US6656929B1 (en) | Pharmaceutical composition with a synthetic natural progesterone and oestradiol base and its preparation process | |
KR20210014168A (ko) | 글루코키나제 활성화제 및 비구아니드 혈당 저하 약물을 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도 | |
CZ214094A3 (en) | Medicaments containing tremadol salt with protracted release of active component | |
EP3003383B1 (en) | Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d | |
US6531151B1 (en) | Composition containing hydroxypropylmethylcellulose and/or ethylcellulose as disintegrants and process for producing it | |
US8187635B2 (en) | Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
EP4051246A1 (en) | Bilayer tablet formulations comprising dapagliflozin and metformin | |
WO2019149917A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
CN110934846A (zh) | 艾地骨化醇胶囊及其制备方法 | |
CN112972410B (zh) | 一种西那卡塞药物组合物片剂及其医药用途 | |
MX2012014402A (es) | Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo. | |
CZ287984B6 (cs) | Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby | |
TWI608849B (zh) | 可調控釋放度之高載藥量之醫藥組合物及其製備方法 | |
KR20160002177A (ko) | 오셀타미비어 유리염기를 포함하는 약학 조성물 | |
CN116159052A (zh) | 联合用药应用以及一种药用组合物及其应用 | |
CN101524355A (zh) | 抗结核药物的复方制剂及其制备方法 | |
WO2015001329A1 (en) | Chewable tablet | |
RU2321405C2 (ru) | Лекарственное средство, обладающее анальгезирующим, жаропонижающим и психостимулирующим действием, и способ его получения | |
WO2020155098A1 (zh) | 一种用于治疗糖尿病的药物组合物及其制备方法和用途 | |
KR20190007370A (ko) | 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 우수한 안정성 및 용출률을 갖는 복합제제 | |
KR20180112139A (ko) | 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 복합제제 | |
RU2810575C1 (ru) | Фармацевтическая композиция, включающая мемантин и цитиколин, а также лекарственная форма на основе указанной фармацевтической композиции, включающей мемантин и цитиколин, способ ее получения и применение лекарственной формы на основе фармацевтической композиции, включающей мемантин и цитиколин | |
CZ20023700A3 (cs) | Farmaceutický prostředek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |